Cover
Cover - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 08, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 001-36533 | |
Entity Registrant Name | MEDAVAIL HOLDINGS, INC. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 90-0772394 | |
Entity Address, Address Line One | 4720 East Cotton Gin Loop, | |
Entity Address, Address Line Two | Suite 220, | |
Entity Address, City or Town | Phoenix, | |
Entity Address, State or Province | AZ | |
Entity Address, Postal Zip Code | 85040 | |
City Area Code | 905 | |
Local Phone Number | 812-0023 | |
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Trading Symbol | MDVL | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 80,045,696 | |
Entity Central Index Key | 0001402479 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 27,196 | $ 19,689 |
Restricted cash | 676 | 400 |
Accounts receivable (net of allowance for doubtful accounts of $186 thousand for September 30, 2022, $66 thousand for December 31, 2021) | 2,262 | 1,189 |
Inventories | 6,401 | 3,916 |
Prepaid expenses and other current assets | 2,863 | 2,191 |
Total current assets | 39,398 | 27,385 |
Property, plant and equipment, net | 6,370 | 5,692 |
Intangible assets, net | 1,580 | 2,300 |
Right-of-use assets | 2,270 | 2,538 |
Other assets | 233 | 228 |
Total assets | 49,851 | 38,143 |
Current liabilities: | ||
Accounts payable | 2,006 | 2,477 |
Accrued liabilities | 1,383 | 1,530 |
Accrued payroll and benefits | 2,869 | 2,733 |
Deferred revenue | 70 | 83 |
Current portion of lease obligations | 728 | 682 |
Total current liabilities | 7,056 | 7,505 |
Long-term debt, net | 9,751 | 9,538 |
Long-term portion of lease obligations | 1,738 | 2,027 |
Total liabilities | 18,545 | 19,070 |
Commitments and contingencies | ||
Stockholders' equity: | ||
Common shares ($0.001 par value, 300,000,000 shares authorized, 80,045,696 and 32,902,048 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively) | 80 | 33 |
Warrants | 11,148 | 1,373 |
Additional paid-in-capital | 255,642 | 216,685 |
Accumulated other comprehensive loss | (6,928) | (6,928) |
Accumulated deficit | (228,636) | (192,090) |
Total stockholders' equity | 31,306 | 19,073 |
Total liabilities and stockholders' equity | $ 49,851 | $ 38,143 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Allowance for doubtful accounts | $ 186 | $ 66 |
Common shares, par value (in USD per share) | $ 0.001 | $ 0.001 |
Common shares, authorized (in shares) | 300,000,000 | 300,000,000 |
Common shares, issued (in shares) | 80,045,696 | 32,902,048 |
Common shares, outstanding (in shares) | 80,045,696 | 32,902,048 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue: | ||||
Total revenue | $ 11,461 | $ 5,792 | $ 31,759 | $ 14,849 |
Cost of products sold and services: | ||||
Total cost of products sold and services | 10,169 | 5,606 | 29,048 | 14,170 |
Operating expense: | ||||
Pharmacy operations | 4,392 | 3,750 | 11,970 | 9,428 |
General and administrative | 6,087 | 5,320 | 18,729 | 16,733 |
Selling and marketing | 2,126 | 1,909 | 6,738 | 5,056 |
Research and development | 178 | 232 | 952 | 601 |
Total operating expense | 12,783 | 11,211 | 38,389 | 31,818 |
Operating loss | (11,491) | (11,025) | (35,678) | (31,139) |
Other gain (loss), net | 0 | 7 | 0 | 206 |
Interest income | 0 | 7 | 1 | 74 |
Interest expense | (315) | (260) | (845) | (328) |
Loss before income taxes | (11,806) | (11,271) | (36,522) | (31,187) |
Income tax expense | 0 | (2) | (24) | (2) |
Net loss | (11,806) | (11,273) | (36,546) | (31,189) |
Comprehensive loss | $ (11,806) | $ (11,273) | $ (36,546) | $ (31,189) |
Net loss per share - basic (in USD per share) | $ (0.15) | $ (0.34) | $ (0.60) | $ (0.96) |
Net loss per share - diluted (in USD per share) | $ (0.15) | $ (0.34) | $ (0.60) | $ (0.96) |
Weighted average shares outstanding - basic (in shares) | 80,045,995 | 32,750,831 | 60,947,511 | 32,580,199 |
Weighted average shares outstanding - diluted (in shares) | 80,045,995 | 32,750,831 | 60,947,511 | 32,580,199 |
Pharmacy and hardware revenue | ||||
Revenue: | ||||
Total revenue | $ 11,266 | $ 5,659 | $ 31,210 | $ 14,165 |
Cost of products sold and services: | ||||
Total cost of products sold and services | 10,113 | 5,539 | 28,827 | 13,744 |
Service revenue | ||||
Revenue: | ||||
Total revenue | 195 | 133 | 549 | 684 |
Cost of products sold and services: | ||||
Total cost of products sold and services | $ 56 | $ 67 | $ 221 | $ 426 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands | Total | Common Shares | Preferred Shares | Warrants | Additional Paid-in-Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | ||
Common Stock, Balance at beginning of period (in shares) at Dec. 31, 2020 | 31,816,020 | ||||||||
Balance at beginning of period at Dec. 31, 2020 | $ 61,067 | $ 32 | $ 0 | [1] | $ 2,614 | $ 213,624 | $ (148,275) | $ (6,928) | |
Preferred Stock, Balance at beginning of period (in shares) at Dec. 31, 2020 | [1] | 0 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net loss | (31,189) | (31,189) | |||||||
Exercise of options (in shares) | 144,101 | ||||||||
Exercise of options | 241 | 241 | |||||||
Exercise of warrants (in shares) | 794,804 | ||||||||
Exercise of warrants | 151 | $ 1 | (1,241) | 1,391 | |||||
Share-based compensation | 948 | 948 | |||||||
Common Stock, Balance at end of period (in shares) at Sep. 30, 2021 | 32,754,925 | ||||||||
Balance at end of period at Sep. 30, 2021 | 31,218 | $ 33 | $ 0 | [1] | 1,373 | 216,204 | (179,464) | (6,928) | |
Preferred Stock, Balance at end of period (in shares) at Sep. 30, 2021 | [1] | 0 | |||||||
Common Stock, Balance at beginning of period (in shares) at Jun. 30, 2021 | 32,583,734 | ||||||||
Balance at beginning of period at Jun. 30, 2021 | 42,099 | $ 33 | $ 0 | [1] | 1,485 | 215,700 | (168,191) | (6,928) | |
Preferred Stock, Balance at beginning of period (in shares) at Jun. 30, 2021 | [1] | 0 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net loss | (11,273) | (11,273) | |||||||
Exercise of warrants (in shares) | 171,191 | ||||||||
Exercise of warrants | 27 | (112) | 139 | ||||||
Share-based compensation | 365 | 365 | |||||||
Common Stock, Balance at end of period (in shares) at Sep. 30, 2021 | 32,754,925 | ||||||||
Balance at end of period at Sep. 30, 2021 | $ 31,218 | $ 33 | $ 0 | [1] | 1,373 | 216,204 | (179,464) | (6,928) | |
Preferred Stock, Balance at end of period (in shares) at Sep. 30, 2021 | [1] | 0 | |||||||
Common Stock, Balance at beginning of period (in shares) at Dec. 31, 2021 | 32,902,048 | 32,902,048 | |||||||
Balance at beginning of period at Dec. 31, 2021 | $ 19,073 | $ 33 | $ 0 | [1] | 1,373 | 216,685 | (192,090) | (6,928) | |
Preferred Stock, Balance at beginning of period (in shares) at Dec. 31, 2021 | [1] | 0 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net loss | (36,546) | (36,546) | |||||||
Issuance of common shares (in shares) | 47,058,820 | ||||||||
Issuance of common shares | 46,961 | $ 47 | 46,914 | ||||||
Issuance of warrants | $ 0 | 9,775 | (9,775) | ||||||
Shares issued for vested RSUs (in shares) | 30,833 | ||||||||
Exercise of options (in shares) | 0 | ||||||||
Exercise of warrants (in shares) | 0 | ||||||||
Issuance of common shares under employee stock purchase plan (in shares) | 53,995 | ||||||||
Issuance of common shares under employee stock purchase plan | $ 77 | 77 | |||||||
Share-based compensation | $ 1,741 | 1,741 | |||||||
Common Stock, Balance at end of period (in shares) at Sep. 30, 2022 | 80,045,696 | 80,045,696 | |||||||
Balance at end of period at Sep. 30, 2022 | $ 31,306 | $ 80 | $ 0 | [1] | 11,148 | 255,642 | (228,636) | (6,928) | |
Preferred Stock, Balance at end of period (in shares) at Sep. 30, 2022 | [1] | 0 | |||||||
Common Stock, Balance at beginning of period (in shares) at Jun. 30, 2022 | 70,609,972 | ||||||||
Balance at beginning of period at Jun. 30, 2022 | 32,787 | $ 71 | $ 0 | [1] | 8,876 | 247,598 | (216,830) | (6,928) | |
Preferred Stock, Balance at beginning of period (in shares) at Jun. 30, 2022 | [1] | 0 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net loss | (11,806) | (11,806) | |||||||
Issuance of common shares (in shares) | 9,411,765 | ||||||||
Issuance of common shares | 9,760 | $ 9 | 9,751 | ||||||
Issuance of warrants | 0 | 2,272 | (2,272) | ||||||
Shares issued for vested RSUs (in shares) | 23,959 | ||||||||
Share-based compensation | $ 565 | 565 | |||||||
Common Stock, Balance at end of period (in shares) at Sep. 30, 2022 | 80,045,696 | 80,045,696 | |||||||
Balance at end of period at Sep. 30, 2022 | $ 31,306 | $ 80 | $ 0 | [1] | $ 11,148 | $ 255,642 | $ (228,636) | $ (6,928) | |
Preferred Stock, Balance at end of period (in shares) at Sep. 30, 2022 | [1] | 0 | |||||||
[1]$0.001 par value, 10,000,000 shares authorized for all periods presented. |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares | Sep. 30, 2022 | Dec. 31, 2021 |
Statement of Stockholders' Equity [Abstract] | ||
Preferred shares, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred shares, authorized (in shares) | 10,000,000 | 10,000,000 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Cash flows from operating activities: | |||||
Net loss | $ (11,806) | $ (11,273) | $ (36,546) | $ (31,189) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||
Depreciation of property, plant, and equipment | 300 | 300 | 891 | 928 | |
Amortization of intangible and leased assets | 2,141 | 877 | |||
Bad debt and other non-cash receivables adjustments | 120 | 47 | |||
Term loan discount amortization and interest accretion on debt | 213 | 0 | |||
Impairment of lease asset | (27) | 0 | |||
Share-based compensation expense | 565 | 365 | 1,741 | 948 | |
PPP loan forgiveness gain | 0 | (161) | |||
Changes in operating assets and liabilities: | |||||
Accounts receivable | (1,193) | 398 | |||
Inventory | (3,354) | (2,511) | |||
Prepaid expenses and other current assets | (672) | 772 | |||
Accounts payable, accrued expenses and other liabilities | (137) | 2,180 | |||
Deferred revenue | (13) | 42 | |||
Operating lease liability due to cash payments | (447) | (505) | |||
Net cash used in operating activities | (37,283) | (28,174) | |||
Cash flows from investing activities: | |||||
Purchase of property, plant and equipment | (804) | (680) | |||
Payment of security deposits | (5) | (45) | |||
Purchase of intangible and other assets | (1,088) | (1,544) | |||
Net cash used in investing activities | (1,897) | (2,269) | |||
Cash flows from financing activities: | |||||
Proceeds from issuance of common shares, net | 46,961 | 0 | |||
Proceeds from issuance of common shares upon exercise of options and warrants | 0 | 392 | |||
Proceeds from issuance of common shares upon exercise of employee stock purchase plan | 77 | 0 | |||
Proceeds from debt | 0 | 10,000 | |||
Payment of debt issuance costs | 0 | (624) | |||
Repayment of debt | 0 | (1,000) | |||
Payments on finance lease obligations | (75) | (46) | |||
Net cash provided by financing activities | 46,963 | 8,722 | |||
Net increase (decrease) in cash, cash equivalents and restricted cash | 7,783 | (21,721) | |||
Cash, cash equivalents and restricted cash at beginning of period | 20,089 | 57,996 | $ 57,996 | ||
Cash, cash equivalents and restricted cash at end of period | $ 27,872 | $ 36,275 | 27,872 | 36,275 | $ 20,089 |
Supplemental cash flow information: | |||||
Cash paid for interest | 603 | 125 | |||
Supplemental noncash investing and financing activities: | |||||
Inventory transferred to property, plant and equipment | 869 | 1,075 | |||
Property, plant and equipment transferred to intangible assets | 0 | 46 | |||
Purchase of property, plant and equipment in accounts payable | 21 | 56 | |||
Purchase of intangible assets in accounts payable | 0 | 398 | |||
Fair value of warrants issued upon closing of private placement | 9,775 | 0 | |||
Lease liabilities arising from obtaining right of use assets: | |||||
Operating leases | 206 | 2,177 | |||
Finance leases | $ 73 | $ 97 |
NATURE OF OPERATIONS
NATURE OF OPERATIONS | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
NATURE OF OPERATIONS | NATURE OF OPERATIONSMedAvail Holdings, Inc., or MedAvail, or the Company, a Delaware corporation formerly known as MYOS RENS Technology, is a pharmacy technology and services company that has developed and commercialized an innovative self-service pharmacy, mobile application, and kiosk. The Company’s principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter facilitates live pharmacist counseling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control. The Company also operates SpotRx, or the Pharmacy, a full-service retail pharmacy utilizing the Company’s automated pharmacy technology. |
GOING CONCERN
GOING CONCERN | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
GOING CONCERN | GOING CONCERN Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to the Company's ability to continue as a going concern. If substantial doubt does exist, then management should determine if there are plans in place which alleviate that doubt. Since inception through September 30, 2022, the Company has continually incurred losses from operations which have been financed primarily by net cash proceeds from the sale of stock from private placements, the sale of redeemable preferred stock and debt. Net cash used in operating activities for nine months ended September 30, 2022 and 2021 was $37.3 million and $28.2 million, respectively. As of September 30, 2022, the Company had $27.2 million in cash and cash equivalents and an accumulated deficit of $228.6 million. In April 2022, the Company completed a private placement, pursuant to which the Company received $40.0 million in gross proceeds, with an additional $10.0 million in gross proceeds received upon the second close that occurred on July 1, 2022, before deducting placement agent commissions and other offering expenses totaling $3.0 million. Additionally, the private placement included warrants, some of which may be callable at the Company’s option beginning on each of the 12 month and 24 month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. See Note 11 for further information regarding the private placement warrants. Due to the Company’s significant and ongoing cash requirements to fund operations, management determined that there is substantial doubt as to the Company’s ability to continue as a going concern. The Company added liquidity resources in 2021 through a senior secured term loan facility with Silicon Valley Bank as described in Note 8, pursuant to which the Company borrowed $10.0 million in aggregate initial term loans. Additionally, as referenced above, the Company raised $40.0 million and $10.0 million in gross proceeds through a private placement that closed in April 2022 and July 2022, respectively. There can be no assurance that the steps management is taking will be successful. If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, the Company may have to significantly reduce operations or delay, scale back or discontinue development and expansion plans. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on continued development and deployment of MedCenter kiosks and SpotRx pharmacy operations and the ability to raise significant additional funding. |
BASIS OF PRESENTATION
BASIS OF PRESENTATION | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
BASIS OF PRESENTATION | BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements as of September 30, 2022 and for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information and in accordance with the rules of the Securities and Exchange Commission ("SEC") applicable to interim reports of companies filing as a smaller reporting company. Accordingly, the unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The condensed consolidated balance sheet as of December 31, 2021 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC on March 29, 2022, or the 2021 Form 10-K. The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-process research and development intangible assets, and impairment of long-lived assets and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are deemed to be necessary. Risks and uncertainties relating to COVID-19 The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact the Company's clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of September 30, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s recoverability of, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s condensed consolidated financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results could differ from these estimates and any such differences may be material to the Company’s financial statements. Principles of consolidation The unaudited condensed consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated. Reclassifications During the fourth quarter of 2021, management reclassified certain operating expenses to reflect the costs attributable to pharmacy operations. Specifically, certain costs were reclassified from general and administrative expenses, to pharmacy operations expenses and selling and marketing expenses. This reclassification had no impact on the operating loss subtotal within the consolidated statements of operations and comprehensive loss. The effect of the reclassifications within the condensed consolidated statement of operations and comprehensive loss for 2021 are as follows (in thousands): Three Months Ended September 30, 2021 Current presentation As previously reported Change Pharmacy operations $ 3,750 $ 2,395 $ 1,355 General and administrative 5,320 6,805 (1,485) Selling and marketing 1,909 1,779 130 $ 10,979 $ 10,979 $ — Nine Months Ended September 30, 2021 Current presentation As previously reported Change Pharmacy operations $ 9,428 $ 6,619 $ 2,809 General and administrative 16,733 19,941 (3,208) Selling and marketing 5,056 4,657 399 $ 31,217 $ 31,217 $ — |
RECENT ACCOUNTING PRONOUNCEMENT
RECENT ACCOUNTING PRONOUNCEMENTS | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Standards Update and Change in Accounting Principle [Abstract] | |
RECENT ACCOUNTING PRONOUNCEMENTS | RECENT ACCOUNTING PRONOUNCEMENTS Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. ASU No. 2016-13 will be effective beginning in the first quarter of the Company's fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements and related disclosures. In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820)”- Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, (“ASU 2022-03”). The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements. Recently Adopted Accounting Standards There was no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s condensed consolidated financial statements through the reporting date. |
EARNINGS (LOSS) PER SHARE
EARNINGS (LOSS) PER SHARE | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
EARNINGS (LOSS) PER SHARE | EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period. The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period from the date of issuance to the exercise date. After these warrants were exercised the related issued and outstanding common shares are included in weighted average shares outstanding: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 39,208 November 18, 2020 May 10, 2021 19,310 November 18, 2020 Outstanding |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS Assets and liabilities measured at fair value on a recurring basis were as follows: Fair Value Hierarchy (in thousands) September 30, 2022 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 27,196 $ 27,196 $ — $ — Restricted cash 676 676 — — Total assets $ 27,872 $ 27,872 $ — $ — Fair Value Hierarchy (in thousands) December 31, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 19,689 $ 19,689 $ — $ — Restricted cash 400 400 — — Total assets $ 20,089 $ 20,089 $ — $ — The carrying amount of the Company's term loan approximates fair value based upon market interest rates available to us for debt of similar risk and maturities. Refer to Note 8, Debt, for further information. |
BALANCE SHEET AND OTHER INFORMA
BALANCE SHEET AND OTHER INFORMATION | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
BALANCE SHEET AND OTHER INFORMATION | BALANCE SHEET AND OTHER INFORMATION Restricted cash The Company considers cash to be restricted when withdrawal or general use is legally restricted. During the nine months ended September 30, 2022, the Company recovered the $0.1 million restricted cash balance outstanding at December 31, 2021, that was held as a guarantee for certain purchasing cards. During the same period, pursuant to a Loan and Security Agreement with Silicon Valley Bank dated June 7, 2021 (see Note 8), the Company issued letters of credit to secure certain operating leases, and the Company is required to maintain a $0.7 million balance with the bank to secure the outstanding letters of credit, of which $0.3 million was issued in February 2022. Due to the nature of the deposit, the balance is classified as restricted cash. Restricted cash is included in the balance for cash, cash equivalents and restricted cash presented in the statements of cash flows. Inventory The following table presents detail of inventory balances: September 30, December 31, (in thousands) 2022 2021 Inventory: MedCenter hardware $ 2,464 $ 1,201 Pharmaceuticals 3,275 2,150 Spare parts 662 565 Total inventory $ 6,401 $ 3,916 Pharmaceutical inventory was recognized in pharmacy and hardware cost of products sold at $9.3 million and $5.0 million during the three months ended September 30, 2022 and 2021, respectively, and $26.4 million and $12.2 million during the nine months ended September 30, 2022 and 2021, respectively. MedCenter hardware was recognized in pharmacy and hardware cost of products sold at $0.01 million and $0.1 million during the three months ended September 30, 2022 and 2021, respectively, and $0.2 million and $0.5 million during the nine months ended September 30, 2022 and 2021, respectively. Prepaid expenses and other current assets The following table presents prepaid expenses and other current assets balances: September 30, December 31, (in thousands) 2022 2021 Prepaid expenses and other current assets: Prepaid MedCenter inventory $ 2,204 $ 1,050 Prepaid insurance 292 509 Other 367 632 Total prepaid expenses and other current assets $ 2,863 $ 2,191 Property, plant and equipment, net The following table presents property, plant and equipment balances: Estimated useful lives September 30, December 31, (in thousands) 2022 2021 Property, plant and equipment: MedCenter equipment 8 years $ 7,525 $ 5,875 IT equipment 1 - 3 years 2,390 2,361 Leasehold improvements lesser of useful life or term of lease 980 880 General plant and equipment 5 - 8 years 619 603 Office furniture and equipment 5 - 8 years 538 394 Vehicles 5 years 54 54 Construction-in-process 481 1,021 Total historical cost 12,587 11,188 Accumulated depreciation (6,217) (5,496) Total property, plant and equipment, net $ 6,370 $ 5,692 Depreciation expense of property and equipment was $0.3 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, and $0.9 million and $0.9 million for the nine months ended September 30, 2022 and 2021, respectively. Depreciation expense included in pharmacy and hardware cost of products sold was $0.03 million and $0.05 million for the three months ended September 30, 2022 and 2021, respectively, and $0.1 million and $0.1 million for the nine months ended September 30, 2022, and 2021, respectively. Intangible assets, net The following table presents intangible asset balances: September 30, December 31, (in thousands) 2022 2021 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 5,321 4,475 Website and mobile application 583 583 Total intangible assets 9,761 8,915 Accumulated amortization: Intellectual property (3,857) (3,857) Software (3,741) (2,175) Website and mobile application (583) (583) Total accumulated amortization (8,181) (6,615) Total intangible assets, net $ 1,580 $ 2,300 No intangible assets were purchased for the three months ended September 30, 2022. The Company purchased $0.7 million of intangible assets for the three months ended September 30, 2021, and $0.9 million and $1.9 million for the nine months ended September 30, 2022 and 2021, respectively. Amortization expense of intangible assets was $1.3 million and $0.1 million for the three months ended September 30, 2022 and 2021, respectively, and $1.6 million and $0.2 million for the nine months ended September 30, 2022 and 2021, respectively, and are included in operating expenses. The Company’s management team is evaluating its existing systems and software. If management were to determine that certain systems or software were to be replaced in order to achieve greater efficiencies, cost savings, or both, the estimated remaining useful life of some IT equipment and intangible assets may be reduced, resulting in higher depreciation and amortization expense, respectively. Lessee leases Balance sheet amounts for lease assets and leases liabilities are as follows: September 30, December 31, (in thousands) 2022 2021 Assets: Operating $ 2,110 $ 2,376 Finance 160 162 Total assets $ 2,270 $ 2,538 Liabilities: Operating: Current $ 632 $ 599 Long-term 1,673 1,947 Finance: Current 96 83 Long-term 65 80 Total liabilities $ 2,466 $ 2,709 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: September 30, December 31, (in thousands) 2022 2021 Operating leases: Weighted-average remaining lease term (years) 3.8 4.2 Weighted-average discount rate 6.9 % 6.9 % Finance leases: Weighted-average remaining lease term (years) 1.8 1.5 Weighted-average discount rate 8.6 % 8.8 % Maturities of operating leases liabilities as of September 30, 2022, are as follows, in thousands: Remaining period in 2022 $ 202 2023 755 2024 617 2025 534 2026 468 2027 64 Thereafter — Total lease payments 2,640 Less: present value discount (335) Total leases $ 2,305 Maturities of finance lease liabilities as of September 30, 2022, are as follows, in thousands: Remaining period in 2022 $ 30 2023 91 2024 49 2025 4 Thereafter — Total finance lease payments 174 Less: imputed interest (13) Total leases $ 161 Operating lease expenses were $0.2 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, and $0.7 million and $0.7 million for the nine months ended September 30, 2022 and 2021, respectively. |
DEBT
DEBT | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
DEBT | DEBT The following table presents debt balances: September 30, December 31, (in thousands) 2022 2021 Term loan 10,162 10,070 Term loan issuance costs, net (411) (532) Total long-term debt, net $ 9,751 $ 9,538 Term loan |
INCOME TAXES
INCOME TAXES | 9 Months Ended |
Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES The Company incurred $0.02 million and zero of income tax expense for the nine months ended September 30, 2022, and 2021, respectively. The income taxes for the periods ended September 30, 2022, are primarily attributed to certain state taxes. The Company continues to be in a loss position as of September 30, 2022. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses. As of September 30, 2022, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the foreseeable future. On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other things, implements a 15% minimum tax on book income of certain large corporations, a 1% excise tax on net stock repurchases and several tax incentives to promote clean energy. The Company has evaluated the impacts of this legislation to the financial statements but does not expect them to be material. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Legal Following MYOS Rens Technology Inc.’s, or MYOS’s and MedAvail, Inc.’s, or MAI's, announcement of the execution of the Merger Agreement on June 30, 2020, MYOS received separate litigation demands from purported MYOS stockholders on September 16, 2020 and October 20, 2020, respectively seeking certain additional disclosures in the Form S-4 Registration Statement filed with the Securities and Exchange Commission on September 2, 2020, collectively, the Demands. Thereafter, on September 23, 2020, a complaint regarding the transactions contemplated within the Merger Agreement was filed in the Supreme Court of the State of New York, County of New York, captioned Faasse v. MYOS RENS Technology Inc., et. al., Index No.: 654644/2020 (NY Supreme Ct., NY Cnty., September 23, 2020), or the New York Complaint. On October 12, 2020, a second complaint regarding the transactions was filed in the District Court of Nevada, Clark County Nevada, captioned Vigil v. Mannello, et. al., Case No. A-20-822848-C, or the Nevada Complaint, and together with the New York Complaint, the Complaints, and collectively with the Demands, the Litigation. The Demands and the Complaints that comprised the Litigation generally alleged that the directors of MYOS breached their fiduciary duties by entering into the Merger Agreement, and MYOS and MAI disseminated an incomplete and misleading Form S-4 Registration Statement. The New York Complaint also alleged MedAvail aided and abetted such breach of fiduciary duties. |
EQUITY, SHARE-BASED COMPENSATIO
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS | EQUITY, SHARE-BASED COMPENSATION AND WARRANTS On June 14, 2022, the Company’s stockholders approved an Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock, par value $0.001, from 100 million shares to a new total of 300 million shares. The Restated Certificate was effective upon filing the Restated Certificate with the Secretary of State of the State of Delaware on June 15, 2022. Private Placement On March 30, 2022, the Company entered into a Securities Purchase Agreement, or Purchase Agreement, with certain purchasers thereto, or the Investors. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Investors in a private placement, or the Private Placement, up to 47.1 million shares, or the Shares, of the Company’s common stock, and to issue warrants, or the Warrants, to purchase up to 23.5 million shares of common stock, or Warrant Shares. The Shares and the Warrants were sold at two closings as further described below, at a price per share of $1.0625. Each Investor purchasing Shares in the Private Placement was issued a Warrant to purchase that number of Warrant Shares equal to 50% of the number of Shares purchased under the Purchase Agreement by such Investor. The Warrants have a per share exercise price of $1.25 and will be exercisable by the holder at any time on or after the issuance date of the Warrant for a period of five years. If the Warrants were exercised in full immediately after issuance by the Investors, the Company would receive additional gross proceeds of up to $29.4 million. In addition, the Warrant terms provide the Company with a call option to force the Warrant holders to exercise up to two-thirds of the warrant shares subject to each Warrant, with one-third of the Warrant Shares being callable beginning on each of the 12 month and 24 month anniversaries of the Warrant issuance dates, in each case until the expiration of the Warrants, and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. If the Company were to exercise the contingent call options immediately after issuance, approximately $19.6 million in gross proceeds could be raised. On April 4, 2022, the first closing of the Private Placement occurred, in which 37.6 million shares of common stock for $40.0 million in gross proceeds, before deducting placement agent commissions and other offering expenses, and Warrants exercisable for up to 18.8 million Warrant Shares were issued by the Company. A second and final closing occurred on July 1, 2022, and the Investors purchased an additional 9.4 million shares of common stock for $10.0 million in additional gross proceeds and Warrants exercisable for up to 4.7 million Warrants Shares. Shelf Registration and Sales Agreement On August 12, 2022, the Company filed a shelf registration statement on Form S-3, or the Shelf, with the SEC in relation to the registration and potential future issuance of common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts, units and/or any combination thereof, in the aggregate amount of up to $150,000,000. The Shelf was declared effective on August 26, 2022. The Company also entered into a sales agreement as of August 12, 2022, or Sales Agreement, with Cowen and Company, LLC, or Cowen, as sales agent, providing for the offering, issuance and sale of up to an aggregate $50,000,000 of the Company’s common stock from time to time at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on the Nasdaq Capital Market or any other trading market for the Company’s common stock in “at-the-market” offerings, under the Shelf. As of September 30, 2022, the Company has not issued and sold any shares of common stock under the Sales Agreement. Share-based compensation The following table presents the Company's expense related to share-based compensation (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Share-based compensation $ 565 $ 365 $ 1,741 $ 948 The share-based compensation expense for the three and nine months ended September 30, 2022 and inclu ded $0.02 million and $0.1 million , re spectively, from employee stock purchase plan expense. The expense remaining to be recognized for unvested option awards from the 2012, 2018, and 2020 plans and the 2022 inducement plan as of September 30, 2022 was $2.4 million, which is expected to be recognized on a weighted average basis over the next 2.7 years. The expense remaining to be recognized for unvested restricted stock units was $2.2 million, which will be recognized on a weighted average basis over the next 2.3 years. The following table presents the Company's outstanding option awards activity during the nine months ended September 30, 2022 : (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 2,848,903 $ 2.78 $ 1.44 $ 104 Granted 2,758,040 1.35 0.98 — Exercised/released — — — — Expired (117,730) 1.99 1.08 5 Forfeited (952,488) 2.52 1.42 111 Outstanding, end of period 4,536,725 $ 1.93 $ 1.15 8.33 $ — Vested and exercisable, end of the period 1,777,907 2.28 1.16 6.79 — Vested and unvested exercisable, end of the period 1,777,907 2.28 1.16 6.79 — Vested and expected to vest, end of the period 4,309,018 1.94 1.15 8.29 — The following table presents the Company's outstanding restricted stock unit activity during the nine months ended September 30, 2022: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 802,740 $ — $ 2.78 $ 1,124 Granted 1,601,824 — 1.41 2,252 Exercised/released (46,009) — $ 1.17 6.32 54 Expired — — — — Forfeited (585,973) — 2.05 791 Outstanding, end of period 1,772,582 $ — $ 1.69 4.93 $ 1,376 Vested and exercisable, end of the period — — — — Vested and unvested exercisable, end of the period — — — — Vested and expected to vest, end of the period 1,628,975 — 1.69 4.92 1,264 An aggregate of 2.8 million and 3.4 million shares of common stock was available for grant under the 2020 Plan as of September 30, 2022 and December 31, 2021, respectively. In April 2022, the Company adopted the MedAvail Holdings, Inc. 2022 Inducement Equity Incentive Plan or the Inducement Plan. The Inducement Plan reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April 8, 2022, the Company issued inducement awards to employees that included options to purchase 426,500 shares of Company common stock, and 426,500 restricted stock units. The inducement stock options have an exercise price of $1.96, and 25% of the shares vest on the one year anniversary of the date that employment commenced, and an additional one forty-eighth (1/48th) of the shares vest monthly thereafter. The inducement restricted stock units vest at one-third (1/3rd) of the shares on the first, second and third yearly anniversaries of March 1, 2022. Warrants During the nine months ended September 30, 2022, 18.8 million warrants were issued from the first closing of the Private Placement in April 2022 with a fair value of $7.5 million. 4.7 million warrants were issued from the second closing of the Private Placement in July 2022 with a fair value of $2.3 million. No warrants were exercised during the nine months ended September 30, 2022. There were 24.2 million related party warrants outstanding as of September 30, 2022. The terms for the warrants issued from the Private Placement were as follows: September 30, 2022 Issue Date Reason for issuance Term (years) Exercise Price (USD) April 4, 2022 Private Placement 5 $ 1.25 July 1, 2022 Private Placement 5 $ 1.25 |
REVENUE AND SEGMENT REPORTING
REVENUE AND SEGMENT REPORTING | 9 Months Ended |
Sep. 30, 2022 | |
Segment Reporting [Abstract] | |
REVENUE AND SEGMENT REPORTING | REVENUE AND SEGMENT REPORTING Operating segments are the individual operations that the chief operating decision maker, or CODM, who is the Company's chief executive officer, reviews for purposes of assessing performance and making resource allocation decisions. The CODM currently receives the monthly management report which includes information to assess performance. The retail pharmacy services and pharmacy technology operating segments both engage in different business activities from which they earn revenues and incur expenses. The Company has the following two reportable segments: Retail Pharmacy Services Segment Retail Pharmacy Services segment revenue consists of products sold directly to consumers at the point of sale. MedAvail recognizes retail pharmacy revenue, net of taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payers (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts. Pharmacy Technology Segment The Pharmacy Technology Segment consists of sales and subscriptions of MedPlatform systems to customers. These agreements include providing the MedCenter prescription dispensing kiosk, software, and maintenance services. This generally includes either an initial lump sum payment upon installation of the MedCenter with monthly payments for software and services following, or monthly payments for the MedCenter along with monthly payments for software and maintenance services for subscription agreements. The following tables present revenue and costs of products sold and services by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Total Three Months Ended September 30, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 11,162 $ — $ 11,162 Hardware — — — Subscription — 104 104 Total pharmacy and hardware revenue 11,162 104 11,266 Service revenue: Software — 94 94 Maintenance and support — 48 48 Installation — — — Professional services and other — 53 53 Total service revenue — 195 195 Total revenue 11,162 299 11,461 Cost of products sold and services 10,047 122 10,169 Segment gross profit $ 1,115 $ 177 1,292 Operating expense: Pharmacy operations 4,392 General and administrative 6,087 Selling and marketing 2,126 Research and development 178 Total operating expense 12,783 Operating loss $ (11,491) Retail Pharmacy Services Pharmacy Technology Total Three Months Ended September 30, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 5,445 $ — $ 5,445 Hardware — 106 106 Subscription — 108 108 Total pharmacy and hardware revenue 5,445 214 5,659 Service revenue: Software — 51 51 Maintenance and support — 44 44 Installation — 11 11 Professional services and other — 27 27 Total service revenue — 133 133 Total revenue 5,445 347 5,792 Cost of products sold and services 5,366 240 5,606 Segment gross profit $ 79 $ 107 186 Operating expense: Pharmacy operations 3,750 General and administrative 5,320 Selling and marketing 1,909 Research and development 232 Total operating expense 11,211 Operating loss $ (11,025) Retail Pharmacy Services Pharmacy Technology Total Nine Months Ended September 30, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 30,652 $ — $ 30,652 Hardware — 236 236 Subscription — 322 322 Total pharmacy and hardware revenue 30,652 558 31,210 Service revenue: Software — 228 228 Maintenance and support — 127 127 Installation — 77 77 Professional services and other — 117 117 Total service revenue — 549 549 Total revenue 30,652 1,107 31,759 Cost of products sold and services 28,460 588 29,048 Segment gross profit $ 2,192 $ 519 2,711 Operating expense: Pharmacy operations 11,970 General and administrative 18,729 Selling and marketing 6,738 Research and development 952 Total operating expense 38,389 Operating loss $ (35,678) Retail Pharmacy Services Pharmacy Technology Total Nine Months Ended September 30, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 13,357 $ — $ 13,357 Hardware — 470 470 Subscription — 338 338 Total pharmacy and hardware revenue 13,357 808 14,165 Service revenue: Software — 125 125 Maintenance and support — 115 115 Installation — 39 39 Professional services and other — 405 405 Total service revenue — 684 684 Total revenue 13,357 1,492 14,849 Cost of products sold and services 13,130 1,040 14,170 Segment gross profit $ 227 $ 452 679 Operating expense: Pharmacy operations 9,428 General and administrative 16,733 Selling and marketing 5,056 Research and development 601 Total operating expense 31,818 Operating loss $ (31,139) The following table presents assets and liabilities by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Corporate Total September 30, 2022 Assets $ 15,939 $ 7,953 $ 25,959 $ 49,851 Liabilities $ 5,841 $ 2,689 $ 10,015 $ 18,545 December 31, 2021 Assets $ 13,641 $ 5,222 $ 19,280 $ 38,143 Liabilities $ 5,618 $ 3,567 $ 9,885 $ 19,070 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets (in thousands): September 30, December 31, 2022 2021 Long-lived assets: United States $ 8,286 $ 7,675 Canada 354 555 Total long-lived assets $ 8,640 $ 8,230 |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Sep. 30, 2022 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | SUBSEQUENT EVENTS Nasdaq Capital Market Listing Qualifications The Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Capital Market (“Nasdaq”) on October 31, 2022 notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion in Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter will not result in the immediate delisting of the Company’s common stock from Nasdaq. The Company has an initial period of 180 calendar days, or until May 1, 2023, to regain compliance with the Bid Price Rule. If the Company is not in compliance with the Bid Price Rule within the first 180 calendar days, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards required by Nasdaq, except for the minimum bid price requirement. |
BASIS OF PRESENTATION (Policies
BASIS OF PRESENTATION (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation | The accompanying unaudited condensed consolidated financial statements as of September 30, 2022 and for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information and in accordance with the rules of the Securities and Exchange Commission ("SEC") applicable to interim reports of companies filing as a smaller reporting company. Accordingly, the unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The condensed consolidated balance sheet as of December 31, 2021 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC on March 29, 2022, or the 2021 Form 10-K. The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, |
Principles of consolidation | Principles of consolidation The unaudited condensed consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated. |
Recent Accounting Pronouncements and Recently Adopted Accounting Standards | RECENT ACCOUNTING PRONOUNCEMENTS Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. ASU No. 2016-13 will be effective beginning in the first quarter of the Company's fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements and related disclosures. In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820)”- Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, (“ASU 2022-03”). The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements. Recently Adopted Accounting Standards There was no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s condensed consolidated financial statements through the reporting date. |
BASIS OF PRESENTATION (Tables)
BASIS OF PRESENTATION (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of Error Corrections and Prior Period Adjustments | The effect of the reclassifications within the condensed consolidated statement of operations and comprehensive loss for 2021 are as follows (in thousands): Three Months Ended September 30, 2021 Current presentation As previously reported Change Pharmacy operations $ 3,750 $ 2,395 $ 1,355 General and administrative 5,320 6,805 (1,485) Selling and marketing 1,909 1,779 130 $ 10,979 $ 10,979 $ — Nine Months Ended September 30, 2021 Current presentation As previously reported Change Pharmacy operations $ 9,428 $ 6,619 $ 2,809 General and administrative 16,733 19,941 (3,208) Selling and marketing 5,056 4,657 399 $ 31,217 $ 31,217 $ — |
EARNINGS (LOSS) PER SHARE (Tabl
EARNINGS (LOSS) PER SHARE (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of Warrants Included in Earnings per Share | The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period from the date of issuance to the exercise date. After these warrants were exercised the related issued and outstanding common shares are included in weighted average shares outstanding: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 39,208 November 18, 2020 May 10, 2021 19,310 November 18, 2020 Outstanding |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis | Assets and liabilities measured at fair value on a recurring basis were as follows: Fair Value Hierarchy (in thousands) September 30, 2022 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 27,196 $ 27,196 $ — $ — Restricted cash 676 676 — — Total assets $ 27,872 $ 27,872 $ — $ — Fair Value Hierarchy (in thousands) December 31, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 19,689 $ 19,689 $ — $ — Restricted cash 400 400 — — Total assets $ 20,089 $ 20,089 $ — $ — |
BALANCE SHEET AND OTHER INFOR_2
BALANCE SHEET AND OTHER INFORMATION (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of Inventory | The following table presents detail of inventory balances: September 30, December 31, (in thousands) 2022 2021 Inventory: MedCenter hardware $ 2,464 $ 1,201 Pharmaceuticals 3,275 2,150 Spare parts 662 565 Total inventory $ 6,401 $ 3,916 |
Schedule of Prepaid Expenses and Other Current Assets | The following table presents prepaid expenses and other current assets balances: September 30, December 31, (in thousands) 2022 2021 Prepaid expenses and other current assets: Prepaid MedCenter inventory $ 2,204 $ 1,050 Prepaid insurance 292 509 Other 367 632 Total prepaid expenses and other current assets $ 2,863 $ 2,191 |
Schedule of Property, Plant and Equipment, Net and Useful Lives | The following table presents property, plant and equipment balances: Estimated useful lives September 30, December 31, (in thousands) 2022 2021 Property, plant and equipment: MedCenter equipment 8 years $ 7,525 $ 5,875 IT equipment 1 - 3 years 2,390 2,361 Leasehold improvements lesser of useful life or term of lease 980 880 General plant and equipment 5 - 8 years 619 603 Office furniture and equipment 5 - 8 years 538 394 Vehicles 5 years 54 54 Construction-in-process 481 1,021 Total historical cost 12,587 11,188 Accumulated depreciation (6,217) (5,496) Total property, plant and equipment, net $ 6,370 $ 5,692 |
Schedule of Finite-Lived Intangible Assets, Net | The following table presents intangible asset balances: September 30, December 31, (in thousands) 2022 2021 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 5,321 4,475 Website and mobile application 583 583 Total intangible assets 9,761 8,915 Accumulated amortization: Intellectual property (3,857) (3,857) Software (3,741) (2,175) Website and mobile application (583) (583) Total accumulated amortization (8,181) (6,615) Total intangible assets, net $ 1,580 $ 2,300 |
Schedule of Lease Assets and Liabilities | Balance sheet amounts for lease assets and leases liabilities are as follows: September 30, December 31, (in thousands) 2022 2021 Assets: Operating $ 2,110 $ 2,376 Finance 160 162 Total assets $ 2,270 $ 2,538 Liabilities: Operating: Current $ 632 $ 599 Long-term 1,673 1,947 Finance: Current 96 83 Long-term 65 80 Total liabilities $ 2,466 $ 2,709 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: September 30, December 31, (in thousands) 2022 2021 Operating leases: Weighted-average remaining lease term (years) 3.8 4.2 Weighted-average discount rate 6.9 % 6.9 % Finance leases: Weighted-average remaining lease term (years) 1.8 1.5 Weighted-average discount rate 8.6 % 8.8 % |
Schedule of Maturities of Operating Lease Liabilities | Maturities of operating leases liabilities as of September 30, 2022, are as follows, in thousands: Remaining period in 2022 $ 202 2023 755 2024 617 2025 534 2026 468 2027 64 Thereafter — Total lease payments 2,640 Less: present value discount (335) Total leases $ 2,305 |
Schedule of Maturities of Finance Lease Liabilities | Maturities of finance lease liabilities as of September 30, 2022, are as follows, in thousands: Remaining period in 2022 $ 30 2023 91 2024 49 2025 4 Thereafter — Total finance lease payments 174 Less: imputed interest (13) Total leases $ 161 |
DEBT (Tables)
DEBT (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
Schedule of Debt | The following table presents debt balances: September 30, December 31, (in thousands) 2022 2021 Term loan 10,162 10,070 Term loan issuance costs, net (411) (532) Total long-term debt, net $ 9,751 $ 9,538 |
EQUITY, SHARE-BASED COMPENSAT_2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
Schedule of MedAvail Share-based Compensation Expense | The following table presents the Company's expense related to share-based compensation (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Share-based compensation $ 565 $ 365 $ 1,741 $ 948 |
Schedule of Outstanding Option Awards Activity | The following table presents the Company's outstanding option awards activity during the nine months ended September 30, 2022 : (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 2,848,903 $ 2.78 $ 1.44 $ 104 Granted 2,758,040 1.35 0.98 — Exercised/released — — — — Expired (117,730) 1.99 1.08 5 Forfeited (952,488) 2.52 1.42 111 Outstanding, end of period 4,536,725 $ 1.93 $ 1.15 8.33 $ — Vested and exercisable, end of the period 1,777,907 2.28 1.16 6.79 — Vested and unvested exercisable, end of the period 1,777,907 2.28 1.16 6.79 — Vested and expected to vest, end of the period 4,309,018 1.94 1.15 8.29 — |
Schedule of Outstanding RSU Awards Activity | The following table presents the Company's outstanding restricted stock unit activity during the nine months ended September 30, 2022: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 802,740 $ — $ 2.78 $ 1,124 Granted 1,601,824 — 1.41 2,252 Exercised/released (46,009) — $ 1.17 6.32 54 Expired — — — — Forfeited (585,973) — 2.05 791 Outstanding, end of period 1,772,582 $ — $ 1.69 4.93 $ 1,376 Vested and exercisable, end of the period — — — — Vested and unvested exercisable, end of the period — — — — Vested and expected to vest, end of the period 1,628,975 — 1.69 4.92 1,264 |
Schedule of Warrants Issued | The terms for the warrants issued from the Private Placement were as follows: September 30, 2022 Issue Date Reason for issuance Term (years) Exercise Price (USD) April 4, 2022 Private Placement 5 $ 1.25 July 1, 2022 Private Placement 5 $ 1.25 |
REVENUE AND SEGMENT REPORTING (
REVENUE AND SEGMENT REPORTING (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Segment Reporting [Abstract] | |
Schedule of Revenue and Costs of Sales by Segment | The following tables present revenue and costs of products sold and services by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Total Three Months Ended September 30, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 11,162 $ — $ 11,162 Hardware — — — Subscription — 104 104 Total pharmacy and hardware revenue 11,162 104 11,266 Service revenue: Software — 94 94 Maintenance and support — 48 48 Installation — — — Professional services and other — 53 53 Total service revenue — 195 195 Total revenue 11,162 299 11,461 Cost of products sold and services 10,047 122 10,169 Segment gross profit $ 1,115 $ 177 1,292 Operating expense: Pharmacy operations 4,392 General and administrative 6,087 Selling and marketing 2,126 Research and development 178 Total operating expense 12,783 Operating loss $ (11,491) Retail Pharmacy Services Pharmacy Technology Total Three Months Ended September 30, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 5,445 $ — $ 5,445 Hardware — 106 106 Subscription — 108 108 Total pharmacy and hardware revenue 5,445 214 5,659 Service revenue: Software — 51 51 Maintenance and support — 44 44 Installation — 11 11 Professional services and other — 27 27 Total service revenue — 133 133 Total revenue 5,445 347 5,792 Cost of products sold and services 5,366 240 5,606 Segment gross profit $ 79 $ 107 186 Operating expense: Pharmacy operations 3,750 General and administrative 5,320 Selling and marketing 1,909 Research and development 232 Total operating expense 11,211 Operating loss $ (11,025) Retail Pharmacy Services Pharmacy Technology Total Nine Months Ended September 30, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 30,652 $ — $ 30,652 Hardware — 236 236 Subscription — 322 322 Total pharmacy and hardware revenue 30,652 558 31,210 Service revenue: Software — 228 228 Maintenance and support — 127 127 Installation — 77 77 Professional services and other — 117 117 Total service revenue — 549 549 Total revenue 30,652 1,107 31,759 Cost of products sold and services 28,460 588 29,048 Segment gross profit $ 2,192 $ 519 2,711 Operating expense: Pharmacy operations 11,970 General and administrative 18,729 Selling and marketing 6,738 Research and development 952 Total operating expense 38,389 Operating loss $ (35,678) Retail Pharmacy Services Pharmacy Technology Total Nine Months Ended September 30, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 13,357 $ — $ 13,357 Hardware — 470 470 Subscription — 338 338 Total pharmacy and hardware revenue 13,357 808 14,165 Service revenue: Software — 125 125 Maintenance and support — 115 115 Installation — 39 39 Professional services and other — 405 405 Total service revenue — 684 684 Total revenue 13,357 1,492 14,849 Cost of products sold and services 13,130 1,040 14,170 Segment gross profit $ 227 $ 452 679 Operating expense: Pharmacy operations 9,428 General and administrative 16,733 Selling and marketing 5,056 Research and development 601 Total operating expense 31,818 Operating loss $ (31,139) |
Schedule of Assets and Liabilities by Segment | The following table presents assets and liabilities by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Corporate Total September 30, 2022 Assets $ 15,939 $ 7,953 $ 25,959 $ 49,851 Liabilities $ 5,841 $ 2,689 $ 10,015 $ 18,545 December 31, 2021 Assets $ 13,641 $ 5,222 $ 19,280 $ 38,143 Liabilities $ 5,618 $ 3,567 $ 9,885 $ 19,070 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets (in thousands): September 30, December 31, 2022 2021 Long-lived assets: United States $ 8,286 $ 7,675 Canada 354 555 Total long-lived assets $ 8,640 $ 8,230 |
GOING CONCERN (Details)
GOING CONCERN (Details) - USD ($) $ in Thousands | 1 Months Ended | 9 Months Ended | 12 Months Ended | |||||
Jul. 01, 2022 | Apr. 04, 2022 | Jul. 31, 2022 | Apr. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Debt Instrument [Line Items] | ||||||||
Operating cash flows | $ (37,283) | $ (28,174) | ||||||
Cash and cash equivalents | 27,196 | $ 19,689 | ||||||
Accumulated deficit | (228,636) | (192,090) | ||||||
Stock issuance costs | $ 3,000 | |||||||
Proceeds from debt | $ 0 | $ 10,000 | ||||||
Term loan | Secured Debt | ||||||||
Debt Instrument [Line Items] | ||||||||
Proceeds from debt | $ 10,000 | |||||||
Minimum | ||||||||
Debt Instrument [Line Items] | ||||||||
Warrants, callable term | 12 months | 12 months | ||||||
Maximum | ||||||||
Debt Instrument [Line Items] | ||||||||
Warrants, callable term | 24 months | 24 months | ||||||
Private Placement | ||||||||
Debt Instrument [Line Items] | ||||||||
Gross proceeds from private placement | $ 10,000 | $ 40,000 | $ 10,000 | $ 40,000 |
BASIS OF PRESENTATION - Reclass
BASIS OF PRESENTATION - Reclassifications (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||
Pharmacy operations | $ 4,392 | $ 3,750 | $ 11,970 | $ 9,428 |
General and administrative | 6,087 | 5,320 | 18,729 | 16,733 |
Selling and marketing | $ 2,126 | 1,909 | $ 6,738 | 5,056 |
Total | 10,979 | 31,217 | ||
As previously reported | ||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||
Pharmacy operations | 2,395 | 6,619 | ||
General and administrative | 6,805 | 19,941 | ||
Selling and marketing | 1,779 | 4,657 | ||
Total | 10,979 | 31,217 | ||
Change | ||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||
Pharmacy operations | 1,355 | 2,809 | ||
General and administrative | (1,485) | (3,208) | ||
Selling and marketing | 130 | 399 | ||
Total | $ 0 | $ 0 |
EARNINGS (LOSS) PER SHARE - War
EARNINGS (LOSS) PER SHARE - Warrants Included in Earnings per Share (Details) | 9 Months Ended |
Sep. 30, 2022 shares | |
Warrants Issued May 9, 2018 | |
Class of Warrant or Right [Line Items] | |
Warrants (in shares) | 118,228 |
Warrants Issued February 11, 2020 | |
Class of Warrant or Right [Line Items] | |
Warrants (in shares) | 309,698 |
Warrants Issued June 29, 2020 | |
Class of Warrant or Right [Line Items] | |
Warrants (in shares) | 84,911 |
Warrants Issued November 18, 2020 | |
Class of Warrant or Right [Line Items] | |
Warrants (in shares) | 39,208 |
Warrants Issued November 18, 2020, Outstanding | |
Class of Warrant or Right [Line Items] | |
Warrants (in shares) | 19,310 |
EARNINGS (LOSS) PER SHARE - Nar
EARNINGS (LOSS) PER SHARE - Narrative (Details) - shares shares in Millions | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Option | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Potentially dilutive option awards excluded from earnings per share calculation (in shares) | 4.5 | 2.9 | |
Warrants | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Potentially dilutive option awards excluded from earnings per share calculation (in shares) | 24.3 | 0.7 |
FAIR VALUE MEASUREMENTS (Detail
FAIR VALUE MEASUREMENTS (Details) - Fair Value, Recurring - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | $ 27,196 | $ 19,689 |
Restricted cash | 676 | 400 |
Total assets | 27,872 | 20,089 |
Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 27,196 | 19,689 |
Restricted cash | 676 | 400 |
Total assets | 27,872 | 20,089 |
Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Restricted cash | 0 | 0 |
Total assets | 0 | 0 |
Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Restricted cash | 0 | 0 |
Total assets | $ 0 | $ 0 |
BALANCE SHEET AND OTHER INFOR_3
BALANCE SHEET AND OTHER INFORMATION - Narrative (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Feb. 28, 2022 | Dec. 31, 2021 | |
Inventory [Line Items] | ||||||
Restricted cash | $ 676,000 | $ 676,000 | $ 400,000 | |||
Letters of credit outstanding, amount | $ 300,000 | |||||
Depreciation of property, plant, and equipment | 300,000 | $ 300,000 | 891,000 | $ 928,000 | ||
Depreciation included in cost of sales | 30,000 | 50,000 | 100,000 | 100,000 | ||
Increase of intangible assets during the period | 0 | 700,000 | 900,000 | 1,900,000 | ||
Amortization of intangible assets | 1,300,000 | 100,000 | 1,600,000 | 200,000 | ||
Operating lease, expense | 200,000 | 300,000 | 700,000 | 700,000 | ||
Pharmacy | ||||||
Inventory [Line Items] | ||||||
Inventory recognized as cost of sales | 9,300,000 | 5,000,000 | 26,400,000 | 12,200,000 | ||
MedCenter | ||||||
Inventory [Line Items] | ||||||
Inventory recognized as cost of sales | 10,000 | $ 100,000 | 200,000 | $ 500,000 | ||
Guarantee for Purchasing Cards | ||||||
Inventory [Line Items] | ||||||
Cash released from restriction | 100,000 | |||||
Letter of Credit Security | ||||||
Inventory [Line Items] | ||||||
Restricted cash | $ 700,000 | $ 700,000 |
BALANCE SHEET AND OTHER INFOR_4
BALANCE SHEET AND OTHER INFORMATION - Inventories (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
MedCenter hardware | $ 2,464 | $ 1,201 |
Pharmaceuticals | 3,275 | 2,150 |
Spare parts | 662 | 565 |
Total inventory | $ 6,401 | $ 3,916 |
BALANCE SHEET AND OTHER INFOR_5
BALANCE SHEET AND OTHER INFORMATION - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Prepaid expenses and other current assets: | ||
Prepaid MedCenter inventory | $ 2,204 | $ 1,050 |
Prepaid insurance | 292 | 509 |
Other | 367 | 632 |
Total prepaid expenses and other current assets | $ 2,863 | $ 2,191 |
BALANCE SHEET AND OTHER INFOR_6
BALANCE SHEET AND OTHER INFORMATION - Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Line Items] | ||
Historical cost | $ 12,587 | $ 11,188 |
Accumulated depreciation | (6,217) | (5,496) |
Total property, plant and equipment, net | $ 6,370 | 5,692 |
MedCenter equipment | ||
Property, Plant and Equipment [Line Items] | ||
Estimated useful lives | 8 years | |
Historical cost | $ 7,525 | 5,875 |
IT equipment | ||
Property, Plant and Equipment [Line Items] | ||
Historical cost | $ 2,390 | 2,361 |
IT equipment | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated useful lives | 1 year | |
IT equipment | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated useful lives | 3 years | |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Historical cost | $ 980 | 880 |
General plant and equipment | ||
Property, Plant and Equipment [Line Items] | ||
Historical cost | $ 619 | 603 |
General plant and equipment | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated useful lives | 5 years | |
General plant and equipment | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated useful lives | 8 years | |
Office furniture and equipment | ||
Property, Plant and Equipment [Line Items] | ||
Historical cost | $ 538 | 394 |
Office furniture and equipment | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated useful lives | 5 years | |
Office furniture and equipment | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated useful lives | 8 years | |
Vehicles | ||
Property, Plant and Equipment [Line Items] | ||
Estimated useful lives | 5 years | |
Historical cost | $ 54 | 54 |
Construction-in-process | ||
Property, Plant and Equipment [Line Items] | ||
Historical cost | $ 481 | $ 1,021 |
BALANCE SHEET AND OTHER INFOR_7
BALANCE SHEET AND OTHER INFORMATION - Intangible Assets, Net (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Finite-Lived Intangible Assets [Line Items] | ||
Gross intangible assets | $ 9,761 | $ 8,915 |
Accumulated amortization | (8,181) | (6,615) |
Total intangible assets, net | 1,580 | 2,300 |
Intellectual property | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross intangible assets | 3,857 | 3,857 |
Accumulated amortization | (3,857) | (3,857) |
Software | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross intangible assets | 5,321 | 4,475 |
Accumulated amortization | (3,741) | (2,175) |
Website and mobile application | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross intangible assets | 583 | 583 |
Accumulated amortization | $ (583) | $ (583) |
BALANCE SHEET AND OTHER INFOR_8
BALANCE SHEET AND OTHER INFORMATION - Leases, Balance Sheet Information (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Assets | ||
Operating | $ 2,110 | $ 2,376 |
Finance | 160 | 162 |
Total assets | 2,270 | 2,538 |
Operating: | ||
Current | 632 | 599 |
Long-term | 1,673 | 1,947 |
Finance: | ||
Current | 96 | 83 |
Long-term | 65 | 80 |
Total liabilities | $ 2,466 | $ 2,709 |
BALANCE SHEET AND OTHER INFOR_9
BALANCE SHEET AND OTHER INFORMATION - Additional Lease Information (Details) | Sep. 30, 2022 | Dec. 31, 2021 |
Operating leases: | ||
Weighted-average remaining lease term (years) | 3 years 9 months 18 days | 4 years 2 months 12 days |
Weighted-average discount rate | 6.90% | 6.90% |
Finance leases: | ||
Weighted-average remaining lease term (years) | 1 year 9 months 18 days | 1 year 6 months |
Weighted-average discount rate | 8.60% | 8.80% |
BALANCE SHEET AND OTHER INFO_10
BALANCE SHEET AND OTHER INFORMATION - Leases, Operating Lease Liability Maturity (Details) $ in Thousands | Sep. 30, 2022 USD ($) |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Remaining period in 2022 | $ 202 |
2023 | 755 |
2024 | 617 |
2025 | 534 |
2026 | 468 |
2027 | 64 |
Thereafter | 0 |
Total lease payments | 2,640 |
Less: present value discount | (335) |
Total leases | $ 2,305 |
BALANCE SHEET AND OTHER INFO_11
BALANCE SHEET AND OTHER INFORMATION - Leases, Finance Lease Liability Maturity (Details) $ in Thousands | Sep. 30, 2022 USD ($) |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Remaining period in 2022 | $ 30 |
2023 | 91 |
2024 | 49 |
2025 | 4 |
Thereafter | 0 |
Total finance lease payments | 174 |
Less: imputed interest | (13) |
Total leases | $ 161 |
DEBT - Schedule of Debt (Detail
DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Debt Instrument [Line Items] | ||
Long-term debt, net | $ 9,751 | $ 9,538 |
Term loan | Secured Debt | ||
Debt Instrument [Line Items] | ||
Term loan | 10,162 | 10,070 |
Term loan issuance costs, net | $ (411) | $ (532) |
DEBT - Narrative (Details)
DEBT - Narrative (Details) - Term loan - Secured Debt | 9 Months Ended |
Sep. 30, 2022 | |
Debt Instrument [Line Items] | |
Debt instrument, interest rate floor | 7.25% |
Interest rate at end of period | 10.25% |
Prime Rate | |
Debt Instrument [Line Items] | |
Variable interest rate spread | 4% |
INCOME TAXES (Details)
INCOME TAXES (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Income Tax Disclosure [Abstract] | ||||
Income tax expense | $ 0 | $ 2 | $ 24 | $ 2 |
EQUITY, SHARE-BASED COMPENSAT_3
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Equity, Narrative (Details) - $ / shares | Sep. 30, 2022 | Jun. 14, 2022 | Jun. 13, 2022 | Dec. 31, 2021 |
Equity [Abstract] | ||||
Common shares, par value (in USD per share) | $ 0.001 | $ 0.001 | $ 0.001 | |
Common shares, authorized (in shares) | 300,000,000 | 300,000,000 | 100,000,000 | 300,000,000 |
EQUITY, SHARE-BASED COMPENSAT_4
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Private Placement and Shelf Registration and Sales Agreement Narrative (Details) $ / shares in Units, shares in Millions, $ in Millions | 1 Months Ended | ||||||
Aug. 12, 2022 USD ($) | Jul. 01, 2022 USD ($) shares | Apr. 04, 2022 USD ($) shares | Jul. 31, 2022 USD ($) | Apr. 30, 2022 USD ($) | Mar. 31, 2022 | Mar. 30, 2022 USD ($) closing $ / shares shares | |
Subsidiary, Sale of Stock [Line Items] | |||||||
Sale of debt and equity securities, authorized amount | $ 150 | ||||||
Sales agreement, offering, issuance, and sale of common stock, authorized amount | $ 50 | ||||||
Minimum | |||||||
Subsidiary, Sale of Stock [Line Items] | |||||||
Warrants, callable term | 12 months | 12 months | |||||
Maximum | |||||||
Subsidiary, Sale of Stock [Line Items] | |||||||
Warrants, callable term | 24 months | 24 months | |||||
Warrant Shares | |||||||
Subsidiary, Sale of Stock [Line Items] | |||||||
Exercise price of warrants issued (in USD per share) | $ / shares | $ 1.25 | ||||||
Term of warrants (in years) | 5 years | ||||||
Proceeds to be received if warrants are exercised in full | $ 29.4 | ||||||
Percentage of warrants callable | 66.67% | ||||||
Exercise the contingent call options, additional equity | $ 19.6 | ||||||
Warrant Shares | Warrants Callable at 12 Months | |||||||
Subsidiary, Sale of Stock [Line Items] | |||||||
Percentage of warrants callable | 33.33% | ||||||
Warrant Shares | Warrants Callable at 24 Months | |||||||
Subsidiary, Sale of Stock [Line Items] | |||||||
Percentage of warrants callable | 33.33% | ||||||
Private Placement | |||||||
Subsidiary, Sale of Stock [Line Items] | |||||||
Number of shares authorized to be sold (in shares) | shares | 47.1 | ||||||
Number of shares called by warrants (in shares) | shares | 23.5 | ||||||
Number of closings | closing | 2 | ||||||
Sale of stock (in USD per share) | $ / shares | $ 1.0625 | ||||||
Warrants issued as a percentage of shares purchased | 50% | ||||||
Number of shares sold or expected to be sold (in shares) | shares | 9.4 | 37.6 | |||||
Gross proceeds from private placement | $ 10 | $ 40 | $ 10 | $ 40 | |||
Number of warrants issued (in shares) | shares | 4.7 | 18.8 |
EQUITY, SHARE-BASED COMPENSAT_5
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Equity [Abstract] | ||||
Share-based compensation expense | $ 565 | $ 365 | $ 1,741 | $ 948 |
EQUITY, SHARE-BASED COMPENSAT_6
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation, Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Apr. 08, 2022 | Sep. 30, 2022 | Sep. 30, 2022 | Apr. 30, 2022 | Dec. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Expense remaining to be recognized | $ 2,400 | $ 2,400 | |||
Weighted average recognition period (in years) | 2 years 8 months 12 days | ||||
Aggregate shares on common stock available for grant (in shares) | 2,800,000 | 2,800,000 | 3,400,000 | ||
Granted (in shares) | 426,500 | 2,758,040 | |||
Exercise price (in USD per share) | $ 1.96 | $ 1.35 | |||
2022 Inducement Equity Incentive Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Number of shares authorized for issuance (in shares) | 1,500,000 | ||||
ESPP | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based compensation | $ 20 | $ 100 | |||
Restricted Stock Units (RSUs) | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Expense remaining to be recognized | $ 2,200 | $ 2,200 | |||
Weighted average recognition period (in years) | 2 years 3 months 18 days | ||||
Granted (in shares) | 426,500 | ||||
Restricted Stock Units (RSUs) | 2022 Inducement Equity Incentive Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Percentage of vesting rights | 33.33% | ||||
Option | Share-based Payment Arrangement, Tranche One | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Percentage of vesting rights | 25% | ||||
Option | Share-based Payment Arrangement, Tranche Two | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Percentage of vesting rights | 2.08% |
EQUITY, SHARE-BASED COMPENSAT_7
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 9 Months Ended | |
Apr. 08, 2022 | Sep. 30, 2022 | |
Number of Awards | ||
Outstanding awards at beginning of period (in shares) | 2,848,903 | |
Granted (in shares) | 426,500 | 2,758,040 |
Exercised/released (in shares) | 0 | |
Expired (in shares) | (117,730) | |
Forfeited (in shares) | (952,488) | |
Outstanding awards at end of period (in shares) | 4,536,725 | |
Awards vested and exercisable (in shares) | 1,777,907 | |
Awards vested and unvested exercisable (in shares) | 1,777,907 | |
Awards vested and expected to vest (in shares) | 4,309,018 | |
Weighted Average Exercise Price | ||
Weighted average exercise price of awards outstanding at beginning of period (in USD per share) | $ 2.78 | |
Weighted average exercise price of awards granted (in USD per share) | $ 1.96 | 1.35 |
Weighted average exercise price of awards exercised/released (in USD per share) | 0 | |
Weighted average exercise price of awards expired (in USD per share) | 1.99 | |
Weighted average exercise price of awards forfeited (in USD per share) | 2.52 | |
Weighted average exercise price of awards outstanding at end of period (in USD per share) | 1.93 | |
Weighted average exercise price of awards vested and exercisable (in USD per share) | 2.28 | |
Weighted average exercise price of awards vested and unvested exercisable (in USD per share) | 2.28 | |
Weighted average exercise price of awards vested and expected to vest (in USD per share) | 1.94 | |
Weighted Average Fair Value | ||
Weighted average fair value of awards outstanding at beginning of period (in USD per share) | 1.44 | |
Grant date fair value of options granted (in USD per share) | 0.98 | |
Weighted average fair value of awards exercised/released (in USD per share) | 0 | |
Weighted average fair value of awards expired (in USD per share) | 1.08 | |
Weighted average fair value of awards forfeited (in USD per share) | 1.42 | |
Weighted average fair value of awards outstanding at end of period (in USD per share) | 1.15 | |
Weighted average fair value of awards vested and exercisable (in USD per share) | 1.16 | |
Weighted average fair value of awards vested and unvested exercisable (in USD per share) | 1.16 | |
Weighted average fair value of awards vested and expected to vest (in USD per share) | $ 1.15 | |
Weighted Average Remaining Contractual Life (Years) | ||
Outstanding, end of period | 8 years 3 months 29 days | |
Vested and exercisable, end of the period | 6 years 9 months 14 days | |
Vested and unvested exercisable, end of the period | 6 years 9 months 14 days | |
Vested and expected to vest, end of the period | 8 years 3 months 14 days | |
Aggregate Intrinsic Value | ||
Aggregate intrinsic value of awards outstanding at beginning of period | $ 104 | |
Aggregate intrinsic value of awards granted | 0 | |
Aggregate intrinsic value of awards exercised/released | 0 | |
Aggregate intrinsic value of awards expired | 5 | |
Aggregate intrinsic value of awards forfeited | 111 | |
Aggregate intrinsic value of awards outstanding at end of period | 0 | |
Aggregate intrinsic value of awards vested and exercisable | 0 | |
Aggregate intrinsic value of awards vested and unvested exercisable | 0 | |
Aggregate intrinsic value of awards vested and expected to vest | $ 0 |
EQUITY, SHARE-BASED COMPENSAT_8
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - RSU Activity (Details) - Restricted Stock Units (RSUs) $ / shares in Units, $ in Thousands | 9 Months Ended |
Sep. 30, 2022 USD ($) $ / shares shares | |
Number of Awards | |
Outstanding awards at beginning of period (in shares) | shares | 802,740 |
Granted (in shares) | shares | 1,601,824 |
Exercised/Released (in shares) | shares | (46,009) |
Expired (in shares) | shares | 0 |
Forfeited (in shares) | shares | (585,973) |
Outstanding awards at end of period (in shares) | shares | 1,772,582 |
Vested and exercisable, end of the period (in shares) | shares | 0 |
Vested and unvested exercisable, end of the period (in shares) | shares | 0 |
Vested and expected to vest, end of the period (in shares) | shares | 1,628,975 |
Weighted Average Share Price on Date of Exercise | |
Weighted average share price on date of exercise (in USD per share) | $ 1.17 |
Weighted Average Fair Value | |
Weighted average fair value of awards outstanding at beginning of period (in USD per share) | 2.78 |
Weighted average grant date fair value of options granted (in USD per share) | 1.41 |
Weighted average fair value of awards exercised/released (in USD per share) | 6.32 |
Weighted average fair value of awards expired (in USD per share) | 0 |
Weighted average fair value of awards cancelled/forfeited (in USD per share) | 2.05 |
Weighted average fair value of awards outstanding at end of period (in USD per share) | 1.69 |
Weighted average fair value of awards vested and exercisable (in USD per share) | 0 |
Weighted average fair value of awards vested and unvested exercisable (in USD per share) | 0 |
Weighted average fair value of awards vested and expected to vest (in USD per share) | $ 1.69 |
Weighted Average Remaining Contractual Life (Years) | |
Weighted average remaining contractual life | 4 years 11 months 4 days |
Vested and expected to vest, end of the period | 4 years 11 months 1 day |
Aggregate Intrinsic Value | |
Aggregate intrinsic value of awards outstanding at beginning of period | $ | $ 1,124 |
Aggregate intrinsic value of awards granted | $ | 2,252 |
Aggregate intrinsic value of awards exercised/released | $ | 54 |
Aggregate intrinsic value of awards expired | $ | 0 |
Aggregate intrinsic value of awards forfeited | $ | 791 |
Aggregate intrinsic value of awards outstanding at end of period | $ | 1,376 |
Aggregate intrinsic value of awards vested and exercisable | $ | 0 |
Aggregate intrinsic value of awards vested and unvested exercisable | $ | 0 |
Aggregate intrinsic value of awards vested and expected to vest | $ | $ 1,264 |
EQUITY, SHARE-BASED COMPENSAT_9
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Warrants, Narrative (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2022 USD ($) shares | |
Class of Warrant or Right [Line Items] | |
Exercise of warrants (in shares) | 0 |
Investors | |
Class of Warrant or Right [Line Items] | |
Warrants (in shares) | 24,200,000 |
Warrants Issued April 04, 2022, Exercise Price | |
Class of Warrant or Right [Line Items] | |
Warrants issued during the period (in shares) | 18,800,000 |
Fair value of warrants | $ | $ 7.5 |
Warrants Issued July 01, 2022, Exercise Price | |
Class of Warrant or Right [Line Items] | |
Warrants issued during the period (in shares) | 4,700,000 |
Fair value of warrants | $ | $ 2.3 |
EQUITY, SHARE-BASED COMPENSA_10
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Schedule of Warrants Issued (Details) | Sep. 30, 2022 $ / shares |
Warrants Issued April 04, 2022, Exercise Price | |
Class of Warrant or Right [Line Items] | |
Term of warrants (in years) | 5 years |
Exercise price of warrants issued (in USD per share) | $ 1.25 |
Warrants Issued July 01, 2022, Exercise Price | |
Class of Warrant or Right [Line Items] | |
Term of warrants (in years) | 5 years |
Exercise price of warrants issued (in USD per share) | $ 1.25 |
REVENUE AND SEGMENT REPORTING -
REVENUE AND SEGMENT REPORTING - Narrative (Details) | 9 Months Ended |
Sep. 30, 2022 segment | |
Segment Reporting [Abstract] | |
Number of reportable segments | 2 |
REVENUE AND SEGMENT REPORTING_2
REVENUE AND SEGMENT REPORTING - Schedule of Revenue and Cost of Sales (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | $ 11,461 | $ 5,792 | $ 31,759 | $ 14,849 |
Total cost of products sold and services | 10,169 | 5,606 | 29,048 | 14,170 |
Operating expense: | 1,292 | 186 | 2,711 | 679 |
Operating expense: | ||||
Pharmacy operations | 4,392 | 3,750 | 11,970 | 9,428 |
General and administrative | 6,087 | 5,320 | 18,729 | 16,733 |
Selling and marketing | 2,126 | 1,909 | 6,738 | 5,056 |
Research and development | 178 | 232 | 952 | 601 |
Total operating expense | 12,783 | 11,211 | 38,389 | 31,818 |
Operating loss | (11,491) | (11,025) | (35,678) | (31,139) |
Total pharmacy and hardware revenue | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 11,266 | 5,659 | 31,210 | 14,165 |
Total cost of products sold and services | 10,113 | 5,539 | 28,827 | 13,744 |
Retail pharmacy revenue | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 11,162 | 5,445 | 30,652 | 13,357 |
Hardware | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 0 | 106 | 236 | 470 |
Subscription | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 104 | 108 | 322 | 338 |
Total service revenue | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 195 | 133 | 549 | 684 |
Total cost of products sold and services | 56 | 67 | 221 | 426 |
Software | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 94 | 51 | 228 | 125 |
Maintenance and support | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 48 | 44 | 127 | 115 |
Installation | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 0 | 11 | 77 | 39 |
Professional services and other | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 53 | 27 | 117 | 405 |
Retail Pharmacy Services | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 11,162 | 5,445 | 30,652 | 13,357 |
Total cost of products sold and services | 10,047 | 5,366 | 28,460 | 13,130 |
Operating expense: | 1,115 | 79 | 2,192 | 227 |
Retail Pharmacy Services | Total pharmacy and hardware revenue | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 11,162 | 5,445 | 30,652 | 13,357 |
Retail Pharmacy Services | Retail pharmacy revenue | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 11,162 | 5,445 | 30,652 | 13,357 |
Retail Pharmacy Services | Hardware | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 0 | 0 | 0 | 0 |
Retail Pharmacy Services | Subscription | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 0 | 0 | 0 | 0 |
Retail Pharmacy Services | Total service revenue | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 0 | 0 | 0 | 0 |
Retail Pharmacy Services | Software | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 0 | 0 | 0 | 0 |
Retail Pharmacy Services | Maintenance and support | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 0 | 0 | 0 | 0 |
Retail Pharmacy Services | Installation | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 0 | 0 | 0 | 0 |
Retail Pharmacy Services | Professional services and other | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 0 | 0 | 0 | 0 |
Pharmacy Technology | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 299 | 347 | 1,107 | 1,492 |
Total cost of products sold and services | 122 | 240 | 588 | 1,040 |
Operating expense: | 177 | 107 | 519 | 452 |
Pharmacy Technology | Total pharmacy and hardware revenue | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 104 | 214 | 558 | 808 |
Pharmacy Technology | Retail pharmacy revenue | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 0 | 0 | 0 | 0 |
Pharmacy Technology | Hardware | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 0 | 106 | 236 | 470 |
Pharmacy Technology | Subscription | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 104 | 108 | 322 | 338 |
Pharmacy Technology | Total service revenue | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 195 | 133 | 549 | 684 |
Pharmacy Technology | Software | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 94 | 51 | 228 | 125 |
Pharmacy Technology | Maintenance and support | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 48 | 44 | 127 | 115 |
Pharmacy Technology | Installation | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | 0 | 11 | 77 | 39 |
Pharmacy Technology | Professional services and other | ||||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||||
Total revenue | $ 53 | $ 27 | $ 117 | $ 405 |
REVENUE AND SEGMENT REPORTING_3
REVENUE AND SEGMENT REPORTING - Schedule of Assets and Liabilities by Segment (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Assets | $ 49,851 | $ 38,143 |
Liabilities | 18,545 | 19,070 |
Operating Segments | Retail Pharmacy Services | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Assets | 15,939 | 13,641 |
Liabilities | 5,841 | 5,618 |
Operating Segments | Pharmacy Technology | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Assets | 7,953 | 5,222 |
Liabilities | 2,689 | 3,567 |
Corporate | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Assets | 25,959 | 19,280 |
Liabilities | $ 10,015 | $ 9,885 |
REVENUE AND SEGMENT REPORTING_4
REVENUE AND SEGMENT REPORTING - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Total long-lived assets | $ 8,640 | $ 8,230 |
United States | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Total long-lived assets | 8,286 | 7,675 |
Canada | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Total long-lived assets | $ 354 | $ 555 |